Patents by Inventor Andreas M. Kany

Andreas M. Kany has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW PqsR INVERSE AGONISTS
    Publication number: 20230286942
    Abstract: The present invention relates to a compounds according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonasaeruginosa or Burkholderia infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: September 14, 2023
    Inventors: Christian Schütz, Martin Empting, Ahmed S. Ahmed, Mostafa Hamed, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
  • N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20230146507
    Abstract: The present invention related to novel inhibitors of metallo-?3-lactamases of formula (I) wherein R1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with ?-lactam antibiotics.
    Type: Application
    Filed: March 23, 2021
    Publication date: May 11, 2023
    Inventors: Rolf W. Hartmann, Jelena Konstantinovic, Jörg Haupenthal, Anna K. Hirsch, Andreas M. Kany, Cansu Kaya, Samir Yahiaoui, Thomas Wichelhaus, Eugen Proschak
  • NOVEL PqsR INVERSE AGONISTS
    Publication number: 20230106506
    Abstract: The present invention relates to a compound according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
    Type: Application
    Filed: December 30, 2020
    Publication date: April 6, 2023
    Inventors: Mostafa Hamed, Ahmed S. Ahmed, Martin Empting, Christian Schütz, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch